SG Americas Securities’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
– Sell
-25,000
Closed -$241K – 3298
2021
Q4
$241K Buy
+25,000
New +$4.3M ﹤0.01% 2570

Other funds holding NVAX

SG Americas Securities's NVAX Position: Q2 2026 in Review

SG Americas Securities reduced its Novavax (NVAX) stake by 53% in Q2 2026, selling an estimated $665K and leaving 66,837 shares worth $630K. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

SG Americas Securities first reported a position in NVAX in Q2 2013 and has held it in 50 quarters since. The position peaked at $14.6M in Q3 2024. 268 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • SG Americas Securities held 66,837 shares of Novavax worth $630K as of Q2 2026.
  • SG Americas Securities sold 74,248 Novavax shares in Q2 2026, an estimated $665K.
  • Novavax made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2190 holding.
  • SG Americas Securities first reported a position in Novavax in Q2 2013 and has held it in 50 quarters since.
  • SG Americas Securities's Novavax position peaked at $14.6M in Q3 2024.
  • 268 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.